SG11202109157TA - Pyrazolopyridine derivatives as inhibitors of pask - Google Patents

Pyrazolopyridine derivatives as inhibitors of pask

Info

Publication number
SG11202109157TA
SG11202109157TA SG11202109157TA SG11202109157TA SG11202109157TA SG 11202109157T A SG11202109157T A SG 11202109157TA SG 11202109157T A SG11202109157T A SG 11202109157TA SG 11202109157T A SG11202109157T A SG 11202109157TA SG 11202109157T A SG11202109157T A SG 11202109157TA
Authority
SG
Singapore
Prior art keywords
pask
inhibitors
pyrazolopyridine derivatives
pyrazolopyridine
derivatives
Prior art date
Application number
SG11202109157TA
Other languages
English (en)
Inventor
Stéphane Beaumont
Xavier Bock
Martinez Daniel Comas
Agnès Joncour
Frédéric Labéguère
Ramos Miriam López
Taoues Temal-Laïb
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of SG11202109157TA publication Critical patent/SG11202109157TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202109157TA 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask SG11202109157TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1902490.0A GB201902490D0 (en) 2019-02-25 2019-02-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PCT/EP2020/054122 WO2020173739A1 (en) 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask

Publications (1)

Publication Number Publication Date
SG11202109157TA true SG11202109157TA (en) 2021-09-29

Family

ID=65998935

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109157TA SG11202109157TA (en) 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask

Country Status (19)

Country Link
US (1) US20220144823A1 (https=)
EP (1) EP3931191B1 (https=)
JP (1) JP2022525121A (https=)
KR (1) KR20210134001A (https=)
CN (1) CN113474344A (https=)
AR (1) AR124749A1 (https=)
AU (1) AU2020229041A1 (https=)
BR (1) BR112021016642A2 (https=)
CA (1) CA3130154A1 (https=)
CO (1) CO2021010485A2 (https=)
ES (1) ES2963409T3 (https=)
GB (1) GB201902490D0 (https=)
IL (1) IL285751A (https=)
MA (1) MA55074A (https=)
MX (1) MX2021010093A (https=)
PH (1) PH12021552032A1 (https=)
SG (1) SG11202109157TA (https=)
TW (1) TW202045505A (https=)
WO (1) WO2020173739A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物
WO2025143152A1 (ja) * 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル-ピラゾロ[1,5-a]ピリジン化合物、およびそのMYLK4阻害剤としての使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2010090716A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US10392389B2 (en) * 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
CA2969265A1 (en) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use
EP3615538B1 (en) * 2017-04-27 2024-02-07 The Brigham and Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling

Also Published As

Publication number Publication date
CA3130154A1 (en) 2020-09-03
TW202045505A (zh) 2020-12-16
MA55074A (fr) 2022-01-05
ES2963409T3 (es) 2024-03-27
MX2021010093A (es) 2021-09-21
BR112021016642A2 (pt) 2021-11-03
KR20210134001A (ko) 2021-11-08
IL285751A (en) 2021-10-31
US20220144823A1 (en) 2022-05-12
PH12021552032A1 (en) 2022-11-14
AU2020229041A1 (en) 2021-10-21
WO2020173739A1 (en) 2020-09-03
EP3931191A1 (en) 2022-01-05
GB201902490D0 (en) 2019-04-10
CN113474344A (zh) 2021-10-01
JP2022525121A (ja) 2022-05-11
EP3931191B1 (en) 2023-10-04
CO2021010485A2 (es) 2021-08-19
AR124749A1 (es) 2023-05-03

Similar Documents

Publication Publication Date Title
IL279256A (en) Sulfonimidamide compounds as inhibitors of interleukin-1 activity
EP3982949A4 (en) MRSA1 INHIBITORS
IL277455A (en) History of aminopyrimidines as CTPS1 inhibitors
IL287717A (en) Pyrrolopyridines are converted as jak inhibitors
IL287902A (en) Methods of administering certain vmat2 inhibitors
IL279452B (en) Pyrazole history as malt1 inhibitors
IL279453B (en) Pyrazole history as malt1 inhibitors
EP4028013A4 (en) MRSA1 INHIBITORS
IL276592A (en) History of Subtirum
IL276887A (en) History of novel chromium as TCR-NCK interaction inhibitors
IL276312A (en) Use of Alkoxypyrazoles as nitrification inhibitors
HUE067997T2 (hu) Szubsztituált 2-tiazolinok mint nitrifikációs inhibitorok
SG11202109157TA (en) Pyrazolopyridine derivatives as inhibitors of pask
IL291785A (en) 6,1- Naphthyridine-converted inhibitors of cdk5
SG11202008851UA (en) Morpholine derivates as inhibitors of vps34
SG11202006394YA (en) Benzotriazole derivatives as corrosion inhibitors
IL291368A (en) Inhibits expression of methadherin
IL286937A (en) History of isochromane as inhibitors of phosphoinositide 3-kinases
ZA202100140B (en) Pyridopyrimidinone derivatives for use as axl inhibitors
HK40066874A (en) Pyrazolopyridine derivatives as inhibitors of pask
IL277578A (en) New salt forms of URAT-1 inhibitors
HK40082014A (en) Inhibitors of hif-2alpha
AU2019900605A0 (en) Inhibitors of necroptosis
HK40043220A (en) Chromene derivatives as inhibitors of tcr-nck interaction
AU2018901681A0 (en) Inhibitors of necroptosis